AR128284A1 - Métodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos - Google Patents
Métodos para tratar a pacientes con una enfermedad mediada por autoanticuerposInfo
- Publication number
- AR128284A1 AR128284A1 ARP230100108A ARP230100108A AR128284A1 AR 128284 A1 AR128284 A1 AR 128284A1 AR P230100108 A ARP230100108 A AR P230100108A AR P230100108 A ARP230100108 A AR P230100108A AR 128284 A1 AR128284 A1 AR 128284A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- frequency
- autoantibody
- mediated disease
- lymphocytes
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 8
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 13
- 230000001404 mediated effect Effects 0.000 abstract 8
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 abstract 6
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 abstract 6
- 239000005557 antagonist Substances 0.000 abstract 6
- 239000003246 corticosteroid Substances 0.000 abstract 6
- 210000004369 blood Anatomy 0.000 abstract 3
- 239000008280 blood Substances 0.000 abstract 3
- 238000000338 in vitro Methods 0.000 abstract 3
- 238000012544 monitoring process Methods 0.000 abstract 2
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Rehabilitation Therapy (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
En la presente descripción se proporcionan métodos para tratar una enfermedad mediada por autoanticuerpos en un sujeto, métodos para monitorear el tratamiento de una enfermedad mediada por autoanticuerpos en un sujeto, en función de la frecuencia de linfocitos B en el sujeto. Reivindicación 1: Un método para monitorear la eficacia del tratamiento de una enfermedad mediada por autoanticuerpos en un sujeto después del tratamiento con un primer antagonista del FcRn, el método comprende: a) medir in vitro la frecuencia de linfocitos B en una muestra de sangre tomada del sujeto; y b) comparar la frecuencia de linfocitos B con un valor de referencia asociado con la enfermedad mediada por autoanticuerpos en el sujeto, en donde el tratamiento no es eficaz si la frecuencia de los linfocitos B en la muestra es mayor o igual al valor de referencia, y en donde el tratamiento es eficaz si la frecuencia de los linfocitos B es menor que el valor de referencia. Reivindicación 2: Un método para tratar una enfermedad mediada por autoanticuerpos en un sujeto que ha recibido un primer antagonista del FcRn y está recibiendo un régimen de dosis de corticoesteroides, el método comprende: a) administrar al sujeto una cantidad terapéuticamente eficaz de un segundo antagonista del FcRn; b) medir in vitro la frecuencia de linfocitos B en una muestra de sangre tomada del sujeto; y c) comparar la frecuencia de linfocitos B con un valor de referencia asociado con la enfermedad mediada por autoanticuerpos en el sujeto, en donde el régimen de dosis de corticoesteroides se mantiene si la frecuencia de linfocitos B en la muestra es mayor o igual que el valor de referencia, o en donde el régimen de dosis de corticoesteroides se reduce gradualmente si la frecuencia de linfocitos B es menor que el valor de referencia. Reivindicación 3: Un segundo antagonista del FcRn para usar en un método para tratar una enfermedad mediada por autoanticuerpos en un sujeto que ha recibido un primer antagonista del FcRn y está recibiendo un régimen de dosis de corticoesteroides, en donde: a) una cantidad terapéuticamente eficaz del segundo antagonista del FcRn se administra al sujeto; b) la frecuencia de linfocitos B en una muestra de sangre tomada del sujeto se mide in vitro; y c) la frecuencia de los linfocitos B se compara con un valor de referencia asociado con la enfermedad mediada por autoanticuerpos en el sujeto, en donde el régimen de dosis de corticoesteroides se mantiene si la frecuencia de linfocitos B en la muestra es mayor o igual que el valor de referencia, y en donde el régimen de dosis de corticoesteroides se reduce gradualmente si la frecuencia de linfocitos B es menor que el valor de referencia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263266852P | 2022-01-17 | 2022-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128284A1 true AR128284A1 (es) | 2024-04-10 |
Family
ID=85036487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100108A AR128284A1 (es) | 2022-01-17 | 2023-01-17 | Métodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR128284A1 (es) |
| AU (1) | AU2023207461A1 (es) |
| CA (1) | CA3241453A1 (es) |
| TW (1) | TW202333791A (es) |
| WO (1) | WO2023135321A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024100453A1 (en) * | 2022-11-07 | 2024-05-16 | argenx BV | Methods for treating lupus nephritis using fcrn antagonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008143954A2 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| KR20200098604A (ko) * | 2017-12-13 | 2020-08-20 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| CA3163172A1 (en) * | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
-
2023
- 2023-01-17 TW TW112102126A patent/TW202333791A/zh unknown
- 2023-01-17 CA CA3241453A patent/CA3241453A1/en active Pending
- 2023-01-17 WO PCT/EP2023/050980 patent/WO2023135321A1/en active Application Filing
- 2023-01-17 AR ARP230100108A patent/AR128284A1/es unknown
- 2023-01-17 AU AU2023207461A patent/AU2023207461A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023207461A1 (en) | 2024-07-11 |
| WO2023135321A1 (en) | 2023-07-20 |
| CA3241453A1 (en) | 2023-07-20 |
| TW202333791A (zh) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ngan Kee et al. | Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery | |
| AR128284A1 (es) | Métodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos | |
| Zhou et al. | The application of molecular imaging to advance translational research in chronic inflammation | |
| Scheiba et al. | Tako-tsubo cardiomyopathy after a hymenoptera sting and treatment with catecholamines | |
| Peng et al. | Delayed onset and protracted course of psoriasis-like secondary syphilitic lesions in a HIV-seropositive man who has sex with men: a case report | |
| Alaca et al. | Clinical significance and prevalence of frailty syndrome in type 2 diabetes patients | |
| Tungsiripat et al. | Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat | |
| Ogunmodede et al. | The use of first line highly active anti-retroviral therapy (HAART) is not associated with QTc prolongation in HIV patients | |
| AU2017286979A1 (en) | Diagnostic or predictor of relapsing remitting multiple sclerosis | |
| kanti Dey et al. | Recurrence of Ischemic Stroke Patients with Common Risk Factors | |
| Ruibin et al. | Clinical features and early diagnosis of acute kidney injury in pationts with COVID-19 | |
| Sawhney et al. | Review of current literature on cutaneous manifestations in covid-19 infection | |
| Belousova et al. | Case 20. Lymphomatoid papulosis type D in a child with CD8+ hypopigmented mycosis fungoides | |
| Amaral et al. | FRI0488 prevalence and clinical significance of cognitive impairment in systemic sclerosis | |
| Liao et al. | The Role of Copeptin in the Diagnosis of Polyuria Polydipsia Syndrome | |
| Mnif et al. | Posterior reversible encephalopathy syndrome in HIV-positive patients: A case report | |
| Liu et al. | Correlations among persistent viral infection, heart function and Chinese medicine syndromes in dilated cardiomyopathy patients | |
| Kulak et al. | Kikuchi-fujimoto disease | |
| Tsygan et al. | Relationship of the myostatin level and secondary sarcopenia in patients undergoing programmed hemodialysis | |
| Pesqué et al. | Reply to'A rare case of adrenergic urticaria in a child'by Schnebert et al | |
| Ceylan et al. | Evaluation of Sarcopenia in COVID-19 Survivors: A Common But Overlooked Problem | |
| Kamath et al. | Fever with rash; Role of an untold history in clinching the diagnosis | |
| Gupta et al. | Prevalence and Characterization of Chronic Kidney Disease Associated Pruritus in Patients Undergoing Maintenance Hemodialysis | |
| RAMAPRIYA et al. | Serum Procalcitonin as a Diagnostic Marker for Systemic Inflammatory Response Syndrome in Intensive Care Unit Patients. | |
| Felten et al. | SAT0470 Myositis, often suspected, is actually rare in primary sjÖgren’s syndrome: data from the french cohort assess |